Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients
Investigators performed a randomized, noninferiority, 96-week, strategic trial of dolutegravir to compare efficacy and effect on lipid parameters.
The approval of Intelence for this patient population was based on an open-label, single arm trial (N=20) which showed that the safety and efficacy of etravirine + an optimized background ...
The FDA has approved Symtuza for the treatment of HIV-1 infection in treatment-naive and in virologically suppressed adults.
Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in patients with HIV-1